Current role of immunotherapy in multiple myeloma

Acta Medica Austriaca

Volumn 25, Issue 3, 1998, Pages 79-85

  Hajek R ^a   Adam, Z ^a   Krivanova A ^a   Doubek, M ^a   Koristek Z ^a   Vorlicek J ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Adoptive cellular therapy; Cytokines; Graft versus myeloma effect; Immunotherapy; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; DENDRITIC CELL; GENE THERAPY; HUMAN; IMMUNIZATION; MULTIPLE MYELOMA; NATURAL KILLER CELL; PROGNOSIS; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; TREATMENT OUTCOME;

EID: 0031689114     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Adam Z, Vorlicek J, Kralova E, et al: Therapy of multiple myeloma. Press, Masaryk University Brno, 1993, pp 1-220.
2. Aguila HL, Weissman I: Hematopoietic stem cells are not direct cytotoxic targets of natural killer cells. Blood 1996;87:1225-1231.
3. Alyea EP, Schlossman RL, Canning C, Collins H, et al: CD-8 depleted donor lymphocyte infusion mediate graft-versus multiple myeloma (MM) effect. Blood 1996;88:10 (suppl 1): 258a (abstr 1021).
4. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
5. Attisano C, Bianchi A, Montacchini L, Carlesso N, et al: Generation of anti-tumor activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haematopoiesis. Br J Haematol 1994;87:494-502.
6. Barlogie B, Jagannath S, Vesole DH, et al: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-793.
7. Bataille R, Barlogie B, Yang Z, et al: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995;86: 685-691.
8. Battaglio S, Napoli P, Beggiato E, Borrione P, et al: Development of vaccines against autologous tumor-derived idiotic in human myeloma: rationale and preparation. Minerva Biotec 1996;8:1.
9. Beaujeaun F, et al: Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin-2 patients with acute lymphoblastic leukemia. Bone Marrow Transplant 1995;15:691-696.
10. Belch AR, Eisenhauer EA, Muldal A, et al: Phase II study of subcutaneous r Hu-interleukin-2 and rHu-interferon alpha-2a in previously treated patients with multiple myeloma. Ann Oncol 1995;6:721-723.
11. Bender A, Sapp M, Schuler G, Steinman RM, and Bhardwaj N: J Immunol Methods 1996, pp 121-135.
12. Benyunes MC, Higuchi C, York A, Lindgren C, et al: Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995;16:283-288.
13. Bensinger WI: Prognostic factors for outcomes after allogeneic stem cell transplantation for multiple myeloma. VI Int. Workshop on Multiple Myeloma, Boston, 1997 (abstr).
14. Bertz H, Burger JA, Kunzmann R, Mertelsmann R, Finke J: Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997;11:281-283.
15. Bjorkstrand B, Ljungman P, Svensson H, et al: Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from The European Group for Blood and marrow Transplantation. Blood 1996;88:4711-4719.
16. Bohlen H, Titzer S, Christensen O, Manzke O, et al: Dendritic cell based idiotype vaccination in multiple myeloma. Blood 1997;90 (suppl 1): 579a (abstr 2577).
17. Borrione P, Montacchini L, Beggiato E, Pileri A, et al: Clinical and immunological studies in advanced cancer patients sequentially treated with anti CD3 monoclonal antibody (OKT3) and interleukin-2. Leukemia Lymphoma 1996;21:325-330.
18. Browman GP, Ruhin S, Walker I, et al: Interferon-alpha-2b (IFN) maintenance therapy prolongs progression-free and overall survival in plasma cell myeloma (PMC): Results of a randomized trial. Proc Am Soc Clin Oncol 1994;13: 408 (abstr 1391).
19. Bukowski RM, McLain D, Finke J: Clinical pharmacokinetics of interleukin 1, Interleukin 2, Interleukin 4, Tumor Necrosis factor, and Macrophage colony-Stimulating Factor. In Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy. Philadelphia, Lippincott-Raven, 1996, pp 609-638.
20. Byrne J, Iqbal A, Davis J, Haynes AP, Russell NH: Autologous OVHD following PBSCT, with evidence for a graft versus myeloma effect. Br J Hematol 1997;97 (suppl 1): 398 (abstr 143).
21. Cunningham D, Powles R, Malpas JS, et al: A randomized trial of maintenance therapy with Intron-A following high dose melphalan and ABMT in myeloma. Proc Am Soc Clin Oncol 1993;12:364 (abstr 1232).
22. Fefer A, Benyunes MC: Interleukin-2 as consolidative immunotherapy after clinical autologous hone marrow transplantation, in Spitzer T, Mazumbder A (eds): Immunotherapy and bone marrow transplantation. Armonk NY, Futura 1995, pp 101-121.
23. Giralt S, Weber D, Colome M, et al: Induction of autologous graft-versus-host-disease in patients with myeloma undergoing high-dose chemotherapy with autologous stem cell rescue. VI Int. Workshop of Multiple Myeloma, Boston 1997 (abstr 6-11).
24. Giralt S, Weber D, Colome M, Dimopoulos M, et al: Phase trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with aulologous stem-cell rescue. J Clin Oncol 1997;15:667-673.
25. Girolomoni G, Ricciardi-Castagnoli P: Dendritic cells hold promise for immunotherapy. Immunology Today 1997;104:18.
26. Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, et al: Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994;84:3017-3025.
27. Gottlieb DJ, Prentice HG, Metha AB, et al: Recombinant interleukin IL-2 in the treatment of multiple myeloma. Br J Haematol 1989;189 (abstr).
28. Grimm EA, Mazumbder A, Zhang HZ and Rosenberg SA: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral lymphocytes, J Exp Med 1982;155:1823-1841.
29. Hajek R, Vasova I, Adam Z and Mayer J: New approaches to management of multiple myeloma. Acta Med Austriaca 1996;23:91-98.
30. Huang Y-W, Richardson JA, and Vitetta E: Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res 1995;55:610-616.
31. Hussein MA, Snyder J, Rayman P, McLain DA, et al: The effect of IL-2 maintenance (Mn) therapy (TX) in on duration of the plateau phase in responding multiple myeloma (MM) patients (PTS): Blood 1997;90 (suppl 1): 307b (abstr 4132).
32. Jones RJ, Hess A: Autologous graft-versus-host disease. In Spitzer T, Mazumbder A (eds): Immunotherapy and Bone Marrow Transplantation. Armonk NY, Futura, 1995, pp 59-69.
33. Klein B: Cytokine, cytokine receptors, transduction signals and oncogenes in human multiple myeloma. Semin Oncol 1995;32:4-19.
34. Klein B, Bataille R: Cytokine network in multiple myeloma 1997. Hematol Oncol Clin North Am 1997;11:273-284.
35. Klein B, Wijdenes J, Zhang X-G, et al: Murine anti-interleukin-6 monoclonal antibody therapy for a patients with plasma cell leukemia. Blood 1991;78:1198-1203.
36. Klingemann HG, Eaves CJ, Barnett MJ, et al: Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994;14:389-396.
37. Kolb HJ, Menzel H, Holler E, Verdonck D, et al: Donor cell transfusion for the treatment of recurrent leukemia after allogeneic bone marrow transplantation. Blood 1997;90 (suppl 1): 46a (abstr 2434).
38. Kornbluth J, Snead T, Page R, et al: Effective treatment of established human myeloma tumors in SCID mice with human natural killer cells and interleukins (IL-2 and IL-4). Blood 1993;82:263a.
39. Kwak LW, Sternas LA, Jagannath S, Siegel D, Munshi NC, Barlogie B: T-cell responses elicited by immunization of multiple myeloma patients with idiotypic M-protein plus GM-CSF in remission after autologous transplantation. Blood 1997;90 (suppl 1): 579a (abstr 2576).
40. Kwak LW, Taub DD, Duffey PL, Bensinger WI, et al: Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 1995;345:1016-1020.
41. Lokhorst HM, Schattenberg A, Cornelissen J, et al: Successful induction of graft-versus-myeloma by donor leukocyte infusion in relapsed multiple myeloma after allogeneic bone marrow transplantation. VI Int. Workshop of Multiple Myeloma, Boston 1997; Syllabus (abstr).
42. Lopez-Jimenez J, Perez-Oteyza J, Munoz A, Parra C, Villalon L, et al: Subcutaneous versus intravenous low-dose IL-2 therapy alter autologous transplantation: results of a prospective, non-randomized study. Bone Marrow Transplant 1997;19:424-434.
43. Ludwig H, Cohen AM, Polliac A, et al: Interferon alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995;6:467-476.
44. Lum LG, Treisman J, Taylor RF, LeFEver A: Phase I/II trial of activated T cells (ATC), IL-2 and GM-CSF after PBSC transplant for stage IIIB or IV breast cancer. Blood 1997:90 (suppl 1 - part 2 of 2), 381b (abstr 4462).
45. Mandelli F, Avvisati G, Amadori S, et al: Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding Io conventional induction chemotherapy. N Engl J Med 1990;322:1430-1434.
46. Margolin KA, Wright C, Forman SJ: Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells. Leukemia 1997;9:723-728.
47. Massaia M, Attisano C, Peola S, Montacchini I, et al: Rapid generation of anti-plasma cell activity in the bone marrow of myeloma patients by CD3 cross-linking. Blood 1993;82:1787-1797.
48. Massaia M, Dianzani U, Bianchi A, Cumponi A, Boccadoro M, Piler A: Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammapathies. Clinical and Experimental Immunology 1988;73: 214-218.
49. Massaia M, Mariani S, Battaglio S, Beggiato E, et al: Idiotypic reactive T cells. VI Int. Workshop Multiple Myeloma. Boston 1997; Syllabus (abstr).
50. Massumoto C, Benyunes MC, et al: Close stimulation of acute graft-versus host disease by interleukin-2 administered after autologous hone marrow transplantation for hematological malignancies. Bone Marrow Transplant 1996;17: 351-356.
51. McSweeney EN, Tobias JS, Blackman G, et al: Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma. Clin Oncol 1993;5:378-383.
52. Miller JS, Klingsporn S, Lund J, Perry EH, Verfaillie C, McGlave P: Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant 1994;14:555-562.
53. Miller JS, Tesmer-Tuck J, Pierson BA, Weisdorf D, et al: Subcutaneous IL-2 after autologous BMT expands NK in vivo hut requires ex vivo high dose IL-2 for maximal activation. Blood 1996;88 (suppl 1): 609a (abstr 2426).
54. Morecki S, Revel-Vilk S, Nabet C, et al: Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-afla2a and interleukin-2. Cancer Immunol Immunother 1992;35:401.
55. Munshi NC: Immunoregulatory mechanisms in multiple myeloma. Hematol Oncol Clin North Am 1997;11:51-69.
56. Munshi NC, Ding LM, Dahe Lu, Korbluth J, Naugler S, Mahavi D, Srivastava A: GM-CSF transduction of the tumor cells provides lasting immune response in multiple myeloma. Blood 1996;88: (suppl 1): 585a (abstr 2330).
57. Munchi NC, Govindarajan R, Drake R, et al: Thymidine Kinase (TK) gene-transduced human lymphocytes can be highly purified, remains fully functional, and are killed efficiently with ganciclovire. Blood 1997;89:1334-1340.
58. Nagler A, Ackerstein A, Naparstek ROE, Kapelushnik J, Slavin S: Implications of donor lymphocyte infusion (DLI) on acute graft versus host disease (GVHD) tolerance in patients in relapse vs remission post matched allogeneic bone marrow transplantation (BMT). Blood 1997;90 (suppl 1): 383b (abstr 4470).
59. Nagler A, Ackerstein A, Naparstek ROE, Slavin S: Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. Blood 1997;89: 3951-3959.
60. Nakajima F, Khanna A, Xu G, Lagman M, et al: Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: Stimulation of molecular programs of eytotoxic killer cells and induction of tumor regression. Medical Science 1994;91:7889-7893.
61. Nishimoto N, Shima Y, Yoshizaki K and Kishimoto T: Myeloma biology and therapy: present status and future developments. Hematol Oncol Clin North Am 1997;11:159-172.
62. Ozaki S, Kosaka M, Wakatsuki S, et al: Immunotherapy of multiple myeloma with monoclonal antibody directed against a plasma cell-specific antigen, HMI.24. Blood 1997;908:3179-3186.
63. Palumbo A, Bruno B, Boccadoro M and Pileri A: Interferon-γ in Multiple Myeloma. Leukemia Lymphoma 1995;18:215-219.
64. Peest D, Deicher H, Coldewey R, et al: Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP. Eur J Cancer Clin Oncol 1988;24:1061-1067.
65. Peest D, Leo R, Bloche S, et al: Low-dose reeombinant interleukin-2 therapy in advanced multiple myeloma. Br J Hematol 1995;89:328-337.
66. Pfeiffer S, Samson D, Apperley J, Gooding R: Ex vivo generation and function of dendritic cells in multiple myeloma. Blood 1996;88 (suppl 1): 392a (abstr 1556).
67. Portier M, Zhang X-G, Caron E, Lu Z-Y, Bataille R, Klein B: γ-Interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6) -dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro. Blood 1993;81:3076-3082.
68. Powles R, Cunningham D, Malpas J, et al: a randomized trial of maintenance interferon following high dose chemotherapy in multiple myeloma. Results 5 1/2 years after accrual of the last patients. Blood 1997;90 (suppl 1): 356a (abstr 1588).
69. Quesada JR, Alexanian R, Kurzrock R, Barlogie B, Saks S, Gutterman JU: Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia. Am J Hematol 1988;29:183-187.
70. Reichardt V, Okada C, Benike C, Long G, et al: Idiotypic vaccination using dendritic cells for multiple myleoma patients after autologous peripheral blood stem cell transplantation. Blood 1996;88 (suppl 1): 481a (abstr 1913).
71. Robinson N, Benyunes MC, Thompson JA, et al: Interleukin-2 after autologous stem cell transplantation for hematological malignancy: a phase I/II study. Bone Marrow Transplant 1997;19:435-442.
72. Rosenberg SA, Lotze MT, Mul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in patients with metastatic cancer. N Eng J Med 1985;313:1486-1492.
73. Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high-dose interleukin-2 alone or in conduction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-632.
74. Salmon SE, Crowley JJ, Grogan TM, et al: Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994;12:2405-2414.
75. Shimazaki C, Atzpodien J, Wisniewski D, et al: Cell-mediated toxicity of interleukin-2 activated lymphocytes against autologous and allogeneic human myeloma cells. Acta Haematol 1988;80:203.
76. Slavin S, Naparstek E, Nagler A, Ackerstein A, et al: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996;87:2195-2204.
77. Stevenson FK: DNA vaccines against B-cells tumors. VI. Int. Workshop on Multiple Myeloma Boston 1997; Syllabus (abstr).
78. Tamura T, Udagawa N, Takashashi N, Miyaura C, et al: Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA 1993;90:11924.
79. Taylor CW, Grogan TM, and Salmon SE: Effect of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms. Blood 1990;75:1114-1118.
80. Togawa A, Sawada S, Amano M, et al: Treatment of multiple myeloma with LAK cells plus interleukin 2 or interleukin 2. SO-Rinsho Ketsueki 1989;30:650-658.
81. Tricot G, Vesole DH, Jagannath S, et al: Graft-versus-myeloma-effect: Proof and principle. Blood 1996;87:1196-1197.
82. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ: Graft-versus-myeloma effect in two cases. Lancet 1996;348 (9023): 346.
83. Verma UN, Areman A, Dickerson SA, et al: Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transplant 1995;15:199-206.
84. Verma UN, Charak B, Rajagopal C, Mazumder A: Interleukin-2 in bone marrow transplantation. In Buckner CD (ed): Technical and biological component of marrow transplantation. Boston, Kluwer, 1995, pp 315-336.
85. Vesole D, Kornbluth J, Jagganath S, Sznol M, et al: Biological response modifiers (BRM) in refractory multiple myeloma (MM): Lack of clinical efficacy of recombinant human interleukin-4 and ALL-trans retinoic acid (ATRA). Blood 1996;88 (suppl 1): 263a (abstr 1037).
86. Vogelsang GB, Hess AD, Altomonte V, Bitton R, et al: Interferons augmentation of autologous graft versus host disease (GVHD). Blood 1996;88 (suppl 1): 129a (abstr 504).
87. Westin J: Interferon therapy during the plateau phase of multiple myeloma: an update of a Swedish multicenter study. Sem Oncol 1991;18 (suppl 7): pp 37-40.
88. Wheatley K: Oxford Meta Analysis on Interferon. VI. Int. workshop on Multiple Myeloma 1997, Boston, Syllabus (abstr).
89. Yi Q, Osterborg A, Bergenbrant S, et al: Idiotype-reactive T-cell subsets and tumor load in monoclonal gammapathies. Blood 1995;86:3043-3049.
90. Young RI, Ranson M, Chang J, Lord B, et al: Phase II trial of rhIL-6 (interleukin-6) prior to and concurrently with VAD (Vincristine, Doxorubicine and Dexamethasone) chemotherapy for patients with multiple myeloma. Eur J Cancer 1997;33:307-311.